Otezla (apremilast) is Celgene's attempt to break into the immunology field currently dominated by the TNF blocker drugs, led by AbbVie's Humira. The oral treatment has a novel mechanism ...
led by AbbVie's Humira. NICE'S change of heart means Otezla can now compete with the TNF drugs as an option for patients who have had an inadequate response to or have been unable to tolerate ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback